ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 371,01
-0,81%
Dow Jones
41 938,45
-1,63%
DAX
20 070,45
-0,75%
Brent Oil
80,365
-0,31%
Bitcoin
91 924,89
-2,71%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Revelation Biosciences Inc (REVB)

  7. Revelation Biosciences Inc (REVB) Actualités

REVB

Revelation Biosciences (REVB)

Revelation Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:REVB
DateHeureSourceTitreSymboleSociété
06/01/202512h00Business WireNasdaq Grants Revelation Biosciences Inc. Continued ListingNASDAQ:REVBRevelation Biosciences Inc
03/12/202414h38Business WireRevelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross ProceedsNASDAQ:REVBRevelation Biosciences Inc
02/12/202412h00Business WireRevelation Biosciences Inc. Announces FDA Acceptance of Gemini INDNASDAQ:REVBRevelation Biosciences Inc
12/11/202412h00Business WireRevelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug SupplyNASDAQ:REVBRevelation Biosciences Inc
08/11/202422h15Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024NASDAQ:REVBRevelation Biosciences Inc
24/09/202412h00Business WireRevelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10NASDAQ:REVBRevelation Biosciences Inc
03/09/202423h09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:REVBRevelation Biosciences Inc
26/08/202422h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
21/08/202423h30Business WireRevelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross ProceedsNASDAQ:REVBRevelation Biosciences Inc
09/08/202422h15Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024NASDAQ:REVBRevelation Biosciences Inc
29/07/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:REVBRevelation Biosciences Inc
24/06/202415h00Business WireRevelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker ActivityNASDAQ:REVBRevelation Biosciences Inc
13/06/202415h21Business WireRevelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of GeminiNASDAQ:REVBRevelation Biosciences Inc
10/05/202422h52Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024NASDAQ:REVBRevelation Biosciences Inc
22/03/202421h15Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023NASDAQ:REVBRevelation Biosciences Inc
13/03/202414h00Business WireRevelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
12/03/202414h00Business WireRevelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth ConferenceNASDAQ:REVBRevelation Biosciences Inc
04/03/202415h00Business WireRevelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of GeminiNASDAQ:REVBRevelation Biosciences Inc
14/02/202402h12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REVBRevelation Biosciences Inc
13/02/202415h00Business WireRevelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
12/02/202416h19Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REVBRevelation Biosciences Inc
05/02/202422h41Business WireRevelation Biosciences Inc. Announces Closing of $6.2 Million Public OfferingNASDAQ:REVBRevelation Biosciences Inc
02/02/202422h06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:REVBRevelation Biosciences Inc
01/02/202412h00Business WireRevelation Biosciences Inc. Announces Pricing of $6.2 Million Public OfferingNASDAQ:REVBRevelation Biosciences Inc
30/01/202421h32Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:REVBRevelation Biosciences Inc
30/01/202415h00Business WireRevelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
23/01/202415h00Business WireRevelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024NASDAQ:REVBRevelation Biosciences Inc
22/12/202323h06Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:REVBRevelation Biosciences Inc
22/12/202319h23Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:REVBRevelation Biosciences Inc
12/12/202322h59Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:REVBRevelation Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:REVB

Dernières Valeurs Consultées

BIT
FLES
Franklin Temp Icav - Fra...
BIT
P1U9X0
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés